With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.
The accelerated approval was based on data from the TRITON2 trial involving metastatic patients with BRCA mutations and homologous recombination deficiency.
Maintenance treatment with Clovis' rucaparib may be a more tolerable maintenance therapy than chemo in platinum-responsive patients with mutations in BRCA1/2 or PALB2.
